Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres

被引:37
作者
Smith, Daniel J. [1 ,2 ,3 ]
Ramsay, Kay A. [4 ,5 ]
Yerkovich, Stephanie T. [2 ,6 ]
Reid, David W. [1 ,2 ,3 ]
Wainwright, Claire E. [4 ,7 ]
Grimwood, Keith [4 ,8 ,9 ]
Bell, Scott C. [1 ,2 ,4 ,5 ]
Kidd, Timothy J. [5 ,10 ]
机构
[1] Prince Charles Hosp, Adult Cyst Fibrosis Ctr, Brisbane, Qld 4032, Australia
[2] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[3] QIMR Berghofer Med Res Inst, Infect & Inflammat Lab, Brisbane, Qld, Australia
[4] Childrens Hlth Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia
[5] QIMR Berghofer Med Res Inst, Lung Bacteria Lab, Brisbane, Qld, Australia
[6] Prince Charles Hosp, Queensland Lung Transplant Serv, Brisbane, Qld 4032, Australia
[7] Lady Cilento Childrens Hosp, Dept Resp Med, Brisbane, Qld, Australia
[8] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia
[9] Gold Coast Univ Hosp, Gold Coast, Qld, Australia
[10] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland
基金
英国医学研究理事会;
关键词
antibiotic resistance; cystic fibrosis; epidemiology; Pseudomonas aeruginosa; treatment; PULMONARY-FUNCTION; RISK-FACTORS; SUSCEPTIBILITY; INFECTIONS; CHILDREN; OUTCOMES; DECLINE; ADULTS; MUCUS;
D O I
10.1111/resp.12714
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background and objective: In cystic fibrosis (CF), chronic Pseudomonas aeruginosa infection is associated with increased morbidity, antibiotic treatments and mortality. By linking Australian CF registry data with a national microbiological data set, we examined the association between where treatment was delivered, its intensity and P. aeruginosa antibiotic resistance. Methods: Sputa were collected from paediatric and adult CF patients attending 18 Australian CF centres. P. aeruginosa antibiotic susceptibilities determined by local laboratories were correlated with clinical characteristics, treatment intensity and infection with strains commonly shared among Australian CF patients. Between-centre differences in treatment and antibiotic resistance were also compared. Results: Large variations in antibiotic usage, maintenance treatment practices and multi-antibiotic resistant P. aeruginosa (MARPA) prevalence exist between Australian CF centres, although the overall proportions of MARPA isolates were similar in paediatric and adult centres (31% vs 35%, P = 0.29). Among paediatric centres, MARPA correlated with intravenous antibiotic usage and the Australian state where treatment was delivered, while azithromycin, reduced lung function and treating state predicted intravenous antibiotic usage. In adult centres, body mass index (BMI) and treating state were associated with MARPA, while intravenous antibiotic use was predicted by gender, BMI, dornase-alpha, azithromycin, lung function and treating state. In adults, P. aeruginosa strains AUST-01 and AUST-02 independently predicted intravenous antibiotic usage. Conclusion: Increased treatment intensity in paediatric centres and the Australian state where treatment was received are both associated with greater risk of MARPA, but not worse clinical outcomes.
引用
收藏
页码:329 / 337
页数:9
相关论文
共 40 条
  • [1] Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact
    Aloush, V
    Navon-Venezia, S
    Seigman-Igra, Y
    Cabili, S
    Carmeli, Y
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) : 43 - 48
  • [2] [Anonymous], 2002, HEALTH-LONDON
  • [3] [Anonymous], 2011, Performance standards for antimicrobial disk susceptibility tests
  • [4] approved standard M2-A11, V11th
  • [5] Bell S.M., 2009, Antibiotic Susceptibility Testing By the CDS Method
  • [6] Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project
    Boyle, Michael P.
    Sabadosa, Kathryn A.
    Quinton, Hebe B.
    Marshall, Bruce C.
    Schechter, Michael S.
    [J]. BMJ QUALITY & SAFETY, 2014, 23 : 15 - 22
  • [7] Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents
    Carmeli, Y
    Troillet, N
    Eliopoulos, GM
    Samore, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1379 - 1382
  • [8] Managing Cystic Fibrosis Strategies That Increase Life Expectancy and Improve Quality of Life
    Cohen-Cymberknoh, Malena
    Shoseyov, David
    Kerem, Eitan
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (11) : 1463 - 1471
  • [9] A COMPARISON OF SURVIVAL, GROWTH, AND PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS IN BOSTON AND TORONTO
    COREY, M
    MCLAUGHLIN, FJ
    WILLIAMS, M
    LEVISON, H
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1988, 41 (06) : 583 - 591
  • [10] Molecular Epidemiology of Chronic Pseudomonas aeruginosa Airway Infections in Cystic Fibrosis
    Cramer, Nina
    Wiehlmann, Lutz
    Ciofu, Oana
    Tamm, Stephanie
    Hoiby, Niels
    Tuemmler, Burkhard
    [J]. PLOS ONE, 2012, 7 (11):